Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer ‌ Robert H. Shoemaker, Reynold A. Panettieri, Steven K. Libutti, Howard S. Hochster, Norman R. Watts, Paul T. Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M. White, Quentin Lawrence, Jeremy Boone, Jason D. Marshall, Rebecca L. Matthews, Brian D. Cholewa, Jeffrey W. Richig, Ben T. Chen, David L. McCormick, Romana Gugensberger, Sonja Höller, Josef M. Penninger, Gerald Wirnsberger

Ստացեք ամբողջական տեքստը

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer. ‌ Robert H Shoemaker, Reynold A Panettieri, Steven K Libutti, Howard S Hochster, Norman R Watts, Paul T Wingfield, Philipp Starkl, Lisabeth Pimenov, Riem Gawish, Anastasiya Hladik, Sylvia Knapp, Daniel Boring, Jonathan M White, Quentin Lawrence, Jeremy Boone, Jason D Marshall, Rebecca L Matthews, Brian D Cholewa, Jeffrey W Richig, Ben T Chen, David L McCormick, Romana Gugensberger, Sonja Höller, Josef M Penninger, Gerald Wirnsberger

Ստացեք ամբողջական տեքստը